Yearly net income, revenues increase at Harrow Health

Harrow Health reported a net income of $18.1 million and revenues of $11.4 million in the fourth quarter of 2018.

This compares with a net loss of $2.8 million and revenues of $7.3 million in 2017’s final quarter, according to a press release.

For the full year, the company, which includes the ophthalmology pharmaceutical compounding business ImprimisRx, had a net income of $14.6 million, or $0.67 per basic share, compared with a net loss of $12 million, or $0.60 per basic share, in 2017.

Total revenues increased from $26.8 million in 2017 to $41.4 million in 2018. Gross ophthalmology revenue increased 72% to $10 million.

Harrow Health reported a net income of $18.1 million and revenues of $11.4 million in the fourth quarter of 2018.

This compares with a net loss of $2.8 million and revenues of $7.3 million in 2017’s final quarter, according to a press release.

For the full year, the company, which includes the ophthalmology pharmaceutical compounding business ImprimisRx, had a net income of $14.6 million, or $0.67 per basic share, compared with a net loss of $12 million, or $0.60 per basic share, in 2017.

Total revenues increased from $26.8 million in 2017 to $41.4 million in 2018. Gross ophthalmology revenue increased 72% to $10 million.